Key Highlights
● China SXT announced a one-for-80 share consolidation on August 5, 2026.
● Class A shares outstanding fall from about 105.7 million to about 1.32 million.
● Cash, cash equivalents and restricted cash were US$28,176,233 at March 31, 2026.
● One customer accounted for 86.95% of fiscal 2026 revenue.
China SXT Pharmaceuticals (NASDAQ:SXTC) has drawn attention because it has recently reshaped its share structure. On August 5, 2026 the company announced a one-for-80 consolidation of its Class A and Class B ordinary shares, effective on August 10, 2026, while keeping its Nasdaq listing and the SXTC trading symbol. A change of that scale sharply reduces the share count and alters per-share figures.
Business and Sector
The company, incorporated in the British Virgin Islands and operating in China, develops, manufactures and sells traditional Chinese medicine pieces, commonly abbreviated to TCMP, under the Suxuantang brand. According to its annual report, its range includes Directly-Oral and After-Soaking-Oral products, and about 95% of its TCMP products are on the national insurance catalogue in the People's Republic of China.
Traditional Chinese medicine is a distinct segment of the wider pharmaceutical sector. Demand is supported by established clinical use in China, but the industry is shaped by government pricing controls, insurance catalogue decisions and regulatory change, all of which can influence revenue and margins for producers such as China SXT.
Latest Announcement and Results
The most recent corporate action is the share consolidation announced on August 5, 2026. The company stated that roughly 105.7 million Class A shares outstanding beforehand would become about 1.32 million afterwards. Fractional shares are rounded up to the next whole share, options and warrants are adjusted proportionately, and the CUSIP number changes to G2161P173.
The company has also filed its annual report on Form 20-F for the fiscal year ended March 31, 2026. A secondary summary dated July 1, 2026 reported revenue of about US$1.1 million, a fall of 35%, and a net loss of about US$6.2 million, which it linked partly to a one-off employee incentive charge of roughly US$5.3 million.
Financials and Context
The annual report shows cash, cash equivalents and restricted cash of US$28,176,233 at March 31, 2026, compared with US$18,129,432 a year earlier. Total current assets were US$34,509,722 against current liabilities of US$4,349,320, which implies working capital of roughly US$30.2 million.
The filing also records that one customer accounted for 86.95% of total revenue in fiscal 2026, up from 68.72% in fiscal 2025. That is an unusually high concentration. Such a small share base can make trading thin and prices volatile.
Risks
The company's own risk disclosures are extensive. They include dependence on a small number of customers and on its founder and chief executive, Mr. Zhou, and the need for substantial additional financing that could dilute existing holders. It also lacks product liability insurance, faces price controls and potential changes to insurance catalogues, and relies on a variable interest entity structure that provides indirect control rather than direct ownership and carries regulatory uncertainty in China.
Other risks include thin trading in the Class A shares, price volatility, compliance with internal control requirements and the possibility of falling short of Nasdaq listing standards in future.
Audited Figures and Customer Concentration
China SXT's one-for-80 consolidation, effective August 10, 2026, takes roughly 105.7 million Class A shares to about 1.32 million. The annual report shows cash, cash equivalents and restricted cash of US$28,176,233 at March 31, 2026, up from US$18,129,432, but one customer accounted for 86.95% of total revenue in fiscal 2026, up from 68.72%.
Items to monitor include any further Nasdaq correspondence, the audited figures in the full Form 20-F, how the company deploys its cash balance, and whether customer concentration eases. Further equity issuance would also be relevant given the small share base and the company's stated need for additional financing.






Please wait processing your request...